RECOMBINANT HUMAN PAPILLOMAVIRUS (HPV) QUADRIVALENT VACCINE - Watsons Health

RECOMBINANT HUMAN PAPILLOMAVIRUS (HPV) QUADRIVALENT VACCINE

In June 2006, the quadrivalent HPV vaccine types 6,11,16,18 (GARDASILTM, manufactured by Merck and Co., Inc., Whitehouse Station, New Jersey) was licensed for use among females aged 9-26 years.

It aims to prevent HPV-type–related cervical cancer, cervical cancer precursors, vaginal and vulvar cancer precursors, and anogenital warts. Efficacy studies are on-going in men.

This vaccine is not recommended for use during pregnancy. Consult your health care professional for more details.

Minor symptoms may occur. If any of symptoms persist or worsen, tell your health care professional promptly.

Precautions

This product may contain inactive ingredients, which can cause allergic reactions or other problems.

 

Interactions

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your health care professional. Do not starts, stop, or change the dosage of any medicines without your doctor’s approval.

Available brand:

  • Gardasil

Related Articles

HUMAN PAPILLOMAVIRUS 9-VALENT VACCINE

The 9-valent vaccine against the human papillomavirus (HPV) is a non-infectious adjuvanted vaccine made using recombinant technology. It contains inactive [...]

HUMAN PAPILLOMAVIRUS VACCINE (TYPE 6, 11, 16, 18)

The quadrivalent vaccine against the human papillomavirus (HPV) is a non-infectious adjuvanted vaccine made using recombinant technology. It contains inactive [...]

HIB CONJUGATE VACCINE (MENINGOCOCCAL PROTEIN CONJUGATE)

HiB Conjugate Vaccine (Meningococcal Protein Conjugate) induces the development of anticapsular antibodies, which protect against infection with Haemophilus influenzae type [...]